TransCode Therapeutics (Nasdaq: RNAZ), a clinical-stage RNA oncology company, has announced a proposed public offering of common stock and pre-funded warrants. The offering, managed by ThinkEquity as the sole placement agent, aims to raise funds for product development activities, including clinical trials for TTX-MC138, their lead therapeutic candidate. The company plans to use the proceeds for IND enabling studies, working capital, and general corporate purposes.
The securities will be offered through a shelf registration statement filed with the SEC. TransCode focuses on treating metastatic disease using RNA therapeutics based on its TTX nanoparticle platform. Their lead candidate targets tumors overexpressing microRNA-10b, a biomarker of metastasis.
暗战 2021 : Do you want to issue new shares again? Are there any stocks that can't be completed? It's clear that it's a fraudulent stock!![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
Jaguar8 OP 暗战 2021 : If they need capital, they can do offering but with dilution and consequently running the risk of price deficiency